Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes
Aim: Evaluation of safety and efficacy of selective balloon-occluded transarterial chemoembolization using polyethylene glycol embolizing microspheres in patients with hepatocellular carcinoma. Materials & methods: Twenty-four consecutive patients were included in this monocentric prospective tr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2021-03-01
|
| Series: | Hepatic Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/hep-2020-0022 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850152832415563776 |
|---|---|
| author | Ana-Maria Bucalau Illario Tancredi Martina Pezzullo Raphael Leveque Simona Picchia Jean-Luc Van Laethem Gontran Verset |
| author_facet | Ana-Maria Bucalau Illario Tancredi Martina Pezzullo Raphael Leveque Simona Picchia Jean-Luc Van Laethem Gontran Verset |
| author_sort | Ana-Maria Bucalau |
| collection | DOAJ |
| description | Aim: Evaluation of safety and efficacy of selective balloon-occluded transarterial chemoembolization using polyethylene glycol embolizing microspheres in patients with hepatocellular carcinoma. Materials & methods: Twenty-four consecutive patients were included in this monocentric prospective trial. Adverse events were evaluated at 24 h and 1 month. Imaging response according to modified response evaluation criteria in solid tumors was assessed at 1, 3 and 6 months. Results: The median time of follow-up was of 22.8 months (interquartile range (IQR) 17.38–26.22). Clinical grade 1/2 toxicities (0% >grade 2) were reported in 25.7% of patients, with abdominal pain being the most frequent complication (17.1%). No 30-days mortalities or liver decompensation were observed. The 1-month follow-up MRI showed an overall response rate of 74.3% Conclusion: Balloon-occluded transarterial chemoembolization was shown to be safe and effective. |
| format | Article |
| id | doaj-art-cc5e2422b1e046df9d3480f3e97b5869 |
| institution | OA Journals |
| issn | 2045-0923 2045-0931 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | Taylor & Francis |
| record_format | Article |
| series | Hepatic Oncology |
| spelling | doaj-art-cc5e2422b1e046df9d3480f3e97b58692025-08-20T02:25:51ZengTaylor & FrancisHepatic Oncology2045-09232045-09312021-03-018110.2217/hep-2020-0022Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomesAna-Maria Bucalau0Illario Tancredi1Martina Pezzullo2Raphael Leveque3Simona Picchia4Jean-Luc Van Laethem5Gontran Verset61Department of Gastroenterology, Hepatopancreatology & Digestive Oncology, Hôpital ERASME, Université libre de Bruxelles (ULB), Brussels, Belgium2Department of Interventional Radiology, Hôpital ERASME, Brussels, Belgium3Department of Radiology, Hôpital ERASME, Brussels, Belgium2Department of Interventional Radiology, Hôpital ERASME, Brussels, Belgium4Department of Radiology, Bordet Institute, Brussels, Belgium1Department of Gastroenterology, Hepatopancreatology & Digestive Oncology, Hôpital ERASME, Université libre de Bruxelles (ULB), Brussels, Belgium1Department of Gastroenterology, Hepatopancreatology & Digestive Oncology, Hôpital ERASME, Université libre de Bruxelles (ULB), Brussels, BelgiumAim: Evaluation of safety and efficacy of selective balloon-occluded transarterial chemoembolization using polyethylene glycol embolizing microspheres in patients with hepatocellular carcinoma. Materials & methods: Twenty-four consecutive patients were included in this monocentric prospective trial. Adverse events were evaluated at 24 h and 1 month. Imaging response according to modified response evaluation criteria in solid tumors was assessed at 1, 3 and 6 months. Results: The median time of follow-up was of 22.8 months (interquartile range (IQR) 17.38–26.22). Clinical grade 1/2 toxicities (0% >grade 2) were reported in 25.7% of patients, with abdominal pain being the most frequent complication (17.1%). No 30-days mortalities or liver decompensation were observed. The 1-month follow-up MRI showed an overall response rate of 74.3% Conclusion: Balloon-occluded transarterial chemoembolization was shown to be safe and effective.https://www.futuremedicine.com/doi/10.2217/hep-2020-0022balloon-occluded transarterial chemoembolization using drug-eluting microsphereshepatocellular carcinomapolyethylene glycol embolizing microspherestranscatheter arterial chemoembolization |
| spellingShingle | Ana-Maria Bucalau Illario Tancredi Martina Pezzullo Raphael Leveque Simona Picchia Jean-Luc Van Laethem Gontran Verset Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes Hepatic Oncology balloon-occluded transarterial chemoembolization using drug-eluting microspheres hepatocellular carcinoma polyethylene glycol embolizing microspheres transcatheter arterial chemoembolization |
| title | Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes |
| title_full | Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes |
| title_fullStr | Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes |
| title_full_unstemmed | Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes |
| title_short | Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes |
| title_sort | balloon occluded chemoembolization for hepatocellular carcinoma a prospective study of safety feasibility and outcomes |
| topic | balloon-occluded transarterial chemoembolization using drug-eluting microspheres hepatocellular carcinoma polyethylene glycol embolizing microspheres transcatheter arterial chemoembolization |
| url | https://www.futuremedicine.com/doi/10.2217/hep-2020-0022 |
| work_keys_str_mv | AT anamariabucalau balloonoccludedchemoembolizationforhepatocellularcarcinomaaprospectivestudyofsafetyfeasibilityandoutcomes AT illariotancredi balloonoccludedchemoembolizationforhepatocellularcarcinomaaprospectivestudyofsafetyfeasibilityandoutcomes AT martinapezzullo balloonoccludedchemoembolizationforhepatocellularcarcinomaaprospectivestudyofsafetyfeasibilityandoutcomes AT raphaelleveque balloonoccludedchemoembolizationforhepatocellularcarcinomaaprospectivestudyofsafetyfeasibilityandoutcomes AT simonapicchia balloonoccludedchemoembolizationforhepatocellularcarcinomaaprospectivestudyofsafetyfeasibilityandoutcomes AT jeanlucvanlaethem balloonoccludedchemoembolizationforhepatocellularcarcinomaaprospectivestudyofsafetyfeasibilityandoutcomes AT gontranverset balloonoccludedchemoembolizationforhepatocellularcarcinomaaprospectivestudyofsafetyfeasibilityandoutcomes |